This challenge targets the hypothesis: **Integrated Multi-Analyte CSF Panel Combining YKL-40, sTREM2, and Neurogranin** **Hypothesis Summary:** ## Mechanistic Overview Integrated Multi-Analyte CSF Panel Combining YKL-40, sTREM2, and Neurogranin starts from the claim that modulating CHI3L1/TREM2/NRGN within the disease context of biomarkers can redirect a disease-relevant process. The original description reads: "## Mechanistic Overview Integrated Multi-Analyte CSF Panel Combining YKL-40, sTREM2, and Neurogranin starts from the claim that modulating CHI3L1/TREM2/NRGN within the disease context of biomarkers can redirect a disease-relevan **Falsifiable Predictions:** 1. Pharmacological modulation of CHI3L1/TREM2/NRGN will alter biomarkers markers in validated models by ≥20% 2. Genetic knockdown of the key target will reproduce the pathological phenotype in ≥2 independent model systems 3. Patient-derived biosamples will show the predicted molecular signature (sensitivity ≥70%, specificity ≥70%) 4. Mechanistic intervention at the proposed node will rescue neuronal viability in vitro by ≥30% **Bounty Tier:** $125,655 USD (composite score 0.757) **Challenge Type:** Open — any team may submit experimental evidence supporting or refuting this hypothesis **Success Criteria:** Peer-reviewed evidence demonstrating mechanistic validation of ≥2 of the 4 predictions, with independent replication.